Loading...
Market
Which phase will human clinical trials of anti-IL-11 therapy reach by end of 2024?
2
Resolution / Starting Odds
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
ClinicalTrials.gov and official announcements from trial sponsors
Story
Study Shows Anti-IL-11 Therapy Extends Male Mouse Lifespan by 22.5%, Female by 25%
Jul 17, 2024, 04:20 PM
A recent study published in Nature has found that inhibiting the pro-inflammatory cytokine interleukin-11 (IL-11) can extend the lifespan of mice by up to 25%. The research demonstrated that both genetic deletion and an anti-IL-11 drug were effective in increasing the lifespans of laboratory mice. The treated mice exhibited fewer age-related health problems and maintained a more youthful appearance, earning them the nickname 'supermodel grannies' in the lab. The median lifespan of male mice increased by 22.5% and female mice by 25%. These findings are significant as anti-IL-11 therapies are already undergoing human clinical trials, raising hopes for potential applications in slowing human ageing.
View original story
Similar markets
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%